02/07/2012 07:35:00

Glaxo, Theravance Get Positive Results From LAMA/LABA (UMEC/VI) in COPD

Related content
02 Feb - 
Adaptimmune and GSK Expand Strategic Immunotherapy Coll..

LONDON--GlaxoSmithKline PLC (GSK.LN) and Theravance, Inc. (THRX) Monday announced positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD

MAIN FACTS:

-The results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease.

-These four studies include two 24-week efficacy studies that compared the combination LAMA/LABA, its components and placebo and two 24-week active comparator studies that compared the combination with the LAMA tiotropium, a widely prescribed maintenance bronchodilator for COPD.

-LAMA/LABA is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, administered by a new dry powder inhaler.

-UMEC/VI is a once-daily investigational medicine currently under development for the maintenance treatment of COPD.

-Write to Razak Musah Baba at razak.baba@dowjones.com

(END) Dow Jones Newswires

July 02, 2012 02:35 ET (06:35 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

OZ Management LP : Form 8.3 - London Stock Exchange Group Plc

30/09/2016 13:53:39
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Admiral Group PLC : Total voting rights

30/09/2016 10:56:00
Admiral Group Plc ("the Company")  30 September 2016  Voting Rights and Capital For the purposes of the Financial Conduct Authority's Disclosure and Tr..

Form 8.5 (EPT/RI) - UK Mail Group plc

30/09/2016 07:58:41
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Zealand upsizes its private placement of new shares and shortens the offer period
2
SFL - Ship Finance International Limited Announces Offering of Convertible Senior Notes
3
Zealand raises DKK 143 million / $22 million through a private placement of new shares
4
Prothena Outlines Phase 2 Development Strategy for PRX003
5
Sun Communities, Inc. Announces Date for Third Quarter 2016 Earnings Release and Conference Call

Related stock quotes

Glaxosmithkline PLC ORD .. 1,640.77 -0.4% Stock price decreasing
GlaxoSmithKline PLC 43.12 0.5% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
30 September 2016 19:33:10
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20160921.1 - EUROWEB4 - 2016-09-30 20:33:10 - 2016-09-30 19:33:10 - 1000 - Website: OKAY